Article
Fatal hepatitis B reactivation following discontinuation of nucleoside analogues for chronic hepatitis B.
Gut - 1 Oct 2002
Lim S G, Wai C T, Rajnakova A, Kajiji T, Guan R
Abstract excerpt
BACKGROUND: Nucleoside analogues such as lamivudine for chronic hepatitis B have an excellent safety profile while patients are on therapy but reactivation flares occur in 19-50% of patients after stopping therapy, some of whom develop liver decompensation. AIMS: To describe and report three cases who developed fatal hepatitis B reactivation after stopping nucleoside analogue therapy. SUBJECTS AND RESULTS: Three...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.